



EOS imaging Expands Presence in Asia with First Installation in Hong Kong

The Chinese University of Hong Kong Adopts EOS® Low Dose 2D/3D Imaging

Paris, April 22, 2015 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, today announced that the Department of Orthopaedics and Traumatology at the Chinese University of Hong Kong (CUHK) is the first hospital in Hong Kong to install the EOS® system.

Since its founding in 1982, the mission of CUHK's orthopedics department has evolved into a commitment to provide the highest quality service in patient care, research and education. The department's clinical work and research is considered among the best and has been published in more than 54 international medical journals, contributing to CUHK ranking among the top 100 medical schools in the world, according to *Thompson Reuters*, "Times Higher Education World University Subjects Rankings"ⁱ.

The university's decision to adopt an EOS® system was guided by the orthopaedic department's emphasis on patient care and a strong commitment to ensure surgeons use industry leading equipment and innovative surgical planning and modeling services.

Marie Meynadier, CEO of EOS imaging, said, "*The Chinese University of Hong Kong is ranked as a leading university for orthopedic care in Asia and we are thrilled by their decision to adopt EOS® for their diagnosis, planning and control imaging. This new installation will strengthen our growing presence in the important Asia-Pacific market where we are investing to deploy our technology.*"

The EOS® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



Next press release: July 21th, 2015

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Antoine Denry / Pierre Laurent

Ph: +33 (0)1 44 71 94 91

eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Calvin Allen

Ph: 646-536-7002

callen@theruthgroup.com

ⁱ <http://www.timeshighereducation.co.uk/world-university-rankings/2013-14/subject-ranking/subject/clinical-pre-clinical-health/institution/chinese-university-of-hong-kong>